Pfizer's Patent Cliff: Can New Drugs Offset $1.1B Annual Hit?

Pfizer faces a looming revenue hit from patent expirations that could test whether its newer products and cost cuts can sustain growth. The company's 2026 guidance includes an expected $1.1 billion unfavorable impact from generic and biosimilar competition for drugs such as Eliquis and Ibrance. Ibrance faces patent expiry in 2027, and Xtandi's U.S. patent protection ends in 2029.

The second quarter showed some progress. Pfizer reported $15.0 billion in revenue, a 1% operational increase year over year. Excluding Comirnaty and Paxlovid, revenue grew 5% operationally. Launched and acquired medicines–a category that includes drugs like Padcev and Vyndaqel–generated $3.2 billion, up 18% operationally. Padcev revenue rose 23% to $667 million, driven by market share gains in bladder cancer. The Vyndaqel family brought in $1.76 billion, up 8% on increased diagnosis rates and international demand.

Management also raised the cost-savings target. Pfizer now expects $5.7 billion in net savings by the end of 2026, with $6.7 billion in total net savings through 2029. These reductions could help offset the revenue pressure from patent losses and support margins.

Hedge fund interest was stable. Insider Monkey tracked 83 funds holding PFE in the first quarter, up from 81 in the prior period. The data shows the increase does not signal a strong bet on the turnaround.

Pfizer's Alpha Score is 66 out of 100, labeled Moderate, according to AlphaScala's proprietary framework. That places the stock in a neutral zone for risk-adjusted return potential. See the PFE stock page for more details.

The numbers reveal a $1.1 billion annual revenue gap from patent losses relative to the $3.2 billion in launched medicine revenue. If Padcev and Vyndaqel slow, or if generic erosion accelerates, the gap widens. On the positive side, Pfizer's pipeline includes obesity and oncology candidates that could become future revenue drivers, though those are not yet factored into near-term guidance.

Pfizer expects its COVID-19 revenue to fall to roughly $4 billion in 2026, down from much higher levels during the pandemic. The company's cost-savings target of $5.7 billion by year-end 2026 provides a buffer. The patent cliff remains the central challenge.